Filana Therapeutics Inc Dossier - Source-backed chat

Filana Therapeutics Inc

FLNANASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)-0.13

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.96Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $46.6M

Shares Outstanding 48.3M diluted

Next Earnings Date29 Oct 2026

Last ex-dividend13 Dec 2012

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Filana Therapeutics Inc. (formerly Cassava Sciences, Inc.) has undergone a complete corporate rebranding and strategic pivot following the failure of its Phase 3 Alzheimer's disease trials for simufilam in late 2024. The company is now solely focused on developing simufilam as an oral small molecule modulator of the filamin A protein to treat central nervous system disorders, specifically Tuberous Sclerosis Complex (TSC)-related epilepsy. While preclinical mouse model data published in 'Epilepsia' in April 2026 supports the biological rationale, the clinical program is currently on a full FDA clinical hold (issued in December 2025). Filana is working to submit the required preclinical data and protocol modifications to lift the hold. With $86.6 million in cash as of March 31, 2026, and an impending $31.25 million cash outflow for a proposed securities class action settlement, the company's cash runway is a critical watchpoint. A 'Hold' rating is recommended until the FDA clinical hold is resolved and clinical progress is established.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$5.00

Mean target$6.50

High · most bullish analyst$8.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$5.0015%

The FDA rejects Filana's response to the clinical hold, demanding further extensive and costly preclinical toxicology or safety studies. The clinical hold remains in place through 2027, severely delaying the pipeline. The cash runway is rapidly depleted by ongoing operational burn and the $31.25 million litigation settlement payment, forcing highly dilutive equity financing at depressed share prices or a complete halt to development.

Base CaseCentral scenario

$6.5060%

Matches the consensus mean

Filana successfully submits its formal response to the FDA's clinical hold letter in the second half of 2026. The FDA reviews and lifts the hold, enabling trial initiation by early 2027. The company pays its $31.25 million class-action settlement, leaving a tighter but manageable cash runway that supports operations into late 2027. Maxim Group's resumed coverage with a Buy rating and $5.00 price target reflects this baseline expectation of regulatory resolution.

Bull CaseUpside scenario

$8.0025%

The FDA lifts the clinical hold on the simufilam IND for TSC-related epilepsy in late 2026, allowing the company to initiate its proof-of-concept clinical trial. Preclinical efficacy translates successfully into human trials, demonstrating a significant reduction in focal-onset seizures for TSC patients, over 60% of whom are currently refractory to existing antiepileptic therapies. The company secures a strategic partnership or non-dilutive funding, extending its cash runway well beyond 2027.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Preclinical validation: Published data in 'Epilepsia' (April 2026) shows simufilam dose-dependently attenuates seizure progression in a mouse model of severe TSC-related epilepsy.
Unmet medical need: Over 60% of the approximately 45,000 TSC patients in the U.S. remain refractory to existing antiepileptic therapies, representing a high-value niche market.
Shedding legacy liabilities: Rebranding from Cassava Sciences to Filana Therapeutics and settling major class-action litigation helps distance the company from past scientific misconduct controversies.

Key Investment Risks

FDA Clinical Hold: The IND is on a full clinical hold, and there is no guarantee that the FDA will accept the company's upcoming response or lift the hold.
Cash Runway Constraints: The cash balance of $86.6 million (as of March 31, 2026) will be significantly reduced by a $31.25 million litigation settlement payment, limiting the runway to support long-term clinical trials without additional funding.
Single-Asset Risk: The company's pipeline is heavily reliant on a single drug candidate, simufilam, which previously failed in Phase 3 trials for Alzheimer's disease.

Thesis Invalidation Triggers

FDA formally refuses to lift the clinical hold after reviewing Filana's complete response submission.
Cash and cash equivalents fall below $30 million before the clinical trial is allowed to initiate.
Any new regulatory or scientific misconduct investigations emerge related to the new preclinical TSC data.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.